JSW
ORMP icon

Journey Strategic Wealth’s Oramed Pharmaceuticals ORMP Stock Holding History

Journey Strategic Wealth’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,489
Closed -$30.2K – 535
2024
Q4 		$30.2K Buy
12,489
+211
+2% +$501 ﹤0.01% 500
2024
Q3 		$30K Buy
12,278
+1,278
+12% +$3.12K ﹤0.01% 507
2024
Q2 		$28.3K Buy
11,000
+552
+5% +$1.31K ﹤0.01% 397
2024
Q1 		$30.5K Buy
+10,448
New +$29.2K ﹤0.01% 314

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Journey Strategic Wealth's ORMP Position: Q1 2025 in Review

Journey Strategic Wealth sold out of Oramed Pharmaceuticals (ORMP) in Q1 2025, closing a stake of 12,489 shares — an estimated $30.2K sold.

Journey Strategic Wealth first reported a position in ORMP in Q1 2024 and held it in 4 quarters. The position peaked at $30.5K in Q1 2024. 52 funds tracked by Wall St. Rank hold ORMP as of Q1 2025.

  • Journey Strategic Wealth reported no remaining Oramed Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Journey Strategic Wealth sold 12,489 Oramed Pharmaceuticals shares in Q1 2025, an estimated $30.2K.
  • Journey Strategic Wealth first reported a position in Oramed Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Journey Strategic Wealth's Oramed Pharmaceuticals position peaked at $30.5K in Q1 2024.
  • 52 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2025.

Based on Journey Strategic Wealth's 13F filing for Q1 2025, filed 6 May 2025.